Glaxo Serevent use in patients with worsening asthma is inappropriate -- "Dear Doctor" letter.
GLAXO SEREVENT USE IN WORSENING ASTHMA "IS INAPPROPRIATE," the company tells health care professionals in a Jan. 16 "Dear Doctor" letter. The letter, sent to 330,000 physicians and 110,000 pharmacists, nurses and respiratory technicians, emphasizes revisions to Serevent (salmeterol xinafoate) labeling that warn against prescribing the inhalation aerosol for patients who have worsening or deteriorating asthma and use in acute asthma attacks. "These changes in the labeling are being made because serious acute respiratory events, including fatalities, have been reported (both in the U.S. and worldwide) in patients receiving Serevent inhalation aerosol," Glaxo states in the letter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth